Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors
NCT00728676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2013-01-18
Summary
To validate the outcome measures and the tolerability of Kuvan treatment in the improvement of behavioral symptoms in 10 selected adults with Phenylketonuria (PKU) with or without mental retardation.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
Shoji Yano
lead OTHER
Principal Investigators
-
Shoji Yano, MD, Ph.D. · University of Southern California
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-08-31
- Primary Completion
- 2010-03-31
- Completion
- 2010-05-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders
NCT01274026 ·Status: COMPLETED
-
Phenylketonuria, Oxidative Stress, and BH4
NCT01395394 ·Status: TERMINATED ·Phase: PHASE2
-
Trial of Kuvan in Lesch-Nyhan Disease
NCT00935753 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A Prospective Clinical Study of Phenylketonuria (PKU)
NCT04452513 ·Status: COMPLETED
-
Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
NCT01732471 ·Status: COMPLETED ·Phase: PHASE3
-
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
NCT00778206 ·Status: COMPLETED
-
A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
NCT03505125 ·Status: COMPLETED
-
Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response
NCT00841100 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria
NCT00634660 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
NCT06147856 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy
NCT00986973 ·Status: COMPLETED ·Phase: NA
-
PKU Skin Stripping
NCT04368624 ·Status: COMPLETED
-
Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
NCT01889862 ·Status: COMPLETED ·Phase: PHASE3
-
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
NCT01924026 ·Status: COMPLETED
-
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
NCT03694353 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of RTX-134 in Adults With Phenylketonuria
NCT04110496 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
NCT01212744 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
NCT07220265 ·Status: RECRUITING ·Phase: NA
-
Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria
NCT01977820 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
NCT01560286 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
NCT00225615 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Synergy on Nutrient Intake and Acceptability in Phenylketonuria (PKU)
NCT03777826 ·Status: COMPLETED ·Phase: NA
-
Antioxidant Signature in Adult Patients With Phenylketonuria
NCT02212288 ·Status: COMPLETED
-
Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
NCT00332189 ·Status: COMPLETED ·Phase: PHASE3